Cause, Development, and Progression of Stiff-Person Syndrome
NCT00030940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2017-07-02
Summary
This study will explore the role of various immune factors involved in producing the disease symptoms in stiff-person syndrome (SPS) and follow disease progression in patients. SPS is a progressive disease in which unexpected noises, touches or stressful events set off muscle spasms and stiffness. It is thought to be an autoimmune disease in which the body produces antibodies that attack certain healthy tissues. A better understanding of the disease may help researchers design new therapies.
Patients of any age with SPS may be eligible for this study, except those who:
* Lack of serum anti-GAD antibodies
* Have very advanced disease that precludes traveling
* Have severe cardiovascular, renal, or other end-organ-disease states
Candidates will be screened with a medical history and physical and neurological examinations to confirm the diagnosis of SPS.
After screening, those enrolled in the study will be followed at the NIH Clinical Center every 6 months for 2 years (months 6, 12, 18, and 24) to have the following tests and procedures:
* Physical and neurological examinations and review of symptoms (every visit)
* Blood draw for routine tests and for research studies (every visit)
* Stiffness assessment (every visit) - Patients are asked a series of questions about their stiffness, which physicians rate according to the number of stiff areas (e.g., 0-no stiff areas; 1-stiffness of the lower trunk; 2-stiffness of the upper trunk, etc.).
* Lymphapheresis (at the beginning of the study and at 12 months) - This is a procedure for collecting large quantities of white blood cells. A needle is placed in a vein in the arm. Blood flows from the vein through a plastic tube (catheter) into a machine that spins the blood, separating it into its components. The white blood cells (lymphocytes) are removed, and the rest of the blood-plasma, red cells and platelets-is returned to the body through a second needle placed in the other arm.
* Electrophysiologic studies - These studies include electromyography and nerve conduction testing. For electromyography, a small needle is inserted into a few muscles and the patient is asked to relax or to contract the muscles. The electrical activity of the muscle cells is recorded and analyzed by a computer. For nerve conduction testing, nerves are stimulated through small wire electrodes attached to the skin, and the response is recorded and analyzed.
* Lumbar puncture (at the beginning of the study and at 12 months) - This procedure is done to examine the cerebrospinal fluid (CSF), which bathes the brain and spinal cord. After a local anesthetic is administered, a needle is inserted in the space between the bones in the lower back where the CSF circulates below the spinal cord. About 2 tablespoons of fluid is collected through the needle.
Conditions
- Stiff-Person Syndrome
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Eligibility
- Min Age
- 25 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-02-11
- Completion
- 2007-12-28
Countries
- United States
Study Locations
More Related Trials
-
Plasma Exchange for Autoimmune Autonomic Failure
NCT00359346 ·Status: COMPLETED
-
Myositis Interstitial Lung Disease Nintedanib Trial
NCT05799755 ·Status: COMPLETED ·Phase: PHASE4
-
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
NCT04480450 ·Status: WITHDRAWN ·Phase: PHASE2
-
IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
NCT02414490 ·Status: COMPLETED
-
Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance
NCT00588822 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab to Treat Neuropathy With Anti-MAG Antibodies
NCT00050245 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
NCT03772587 ·Status: COMPLETED ·Phase: PHASE2
-
Sacral Nerve Stimulation for Mild-to-Moderate or Refractory Rheumatoid Arthritis
NCT04821050 ·Status: UNKNOWN ·Phase: NA
-
InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT04529291 ·Status: WITHDRAWN ·Phase: NA
-
A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
NCT04948554 ·Status: TERMINATED ·Phase: PHASE1
-
Clinical Prognosis and Progression of Myasthenia Gravis Patients
NCT04101578 ·Status: UNKNOWN
-
Study of Pioglitazone in Sporadic Inclusion Body Myositis
NCT03440034 ·Status: COMPLETED ·Phase: PHASE1
-
Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity
NCT06169150 ·Status: RECRUITING
-
Intratympanic Steroid for Bell's Palsy
NCT03508440 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
NCT06002945 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
NCT05721573 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
NCT01813617 ·Status: COMPLETED
-
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT04881682 ·Status: RECRUITING ·Phase: PHASE2
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
NCT02110706 ·Status: COMPLETED ·Phase: PHASE2
-
Neuropathy and Anti-GFAP Antibodies
NCT05742087 ·Status: UNKNOWN
-
TNFα Monoclonal Antibody for Acute Spinal Cord Injury
NCT04988425 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)
NCT01257828 ·Status: COMPLETED ·Phase: PHASE3
-
Sporadic Inclusion Body Myositis Natural History Study
NCT05046821 ·Status: ACTIVE_NOT_RECRUITING
-
Rituximab in Systemic Sclerosis
NCT01748084 ·Status: COMPLETED ·Phase: PHASE2/PHASE3